Using combinative in vitro and in vivo studies, we demonstrated that Dot1L is a critical component of pro-fibrotic signaling in the heart, and determined the therapeutic potential of specific inhibitor EPZ5676 in cardiac fibrosis of post-MI. This evidence concerns the gene DOT1L and fibrosis.